Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Articles

Industry groups offered perspectives on the strengths and weaknesses of the European Falsified Medicines Directive.

Implications for APIs in the European Falsified Medicines Directive

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

The investment activity of CDMOs and CMOs reveals the broader business and technical trends of the pharmaceutical industry.

Tracking the Expansion Activities of Contract Service Providers

External manufacturing plays a crucial role in pharmaceutical companies’ supply strategy. The author examines market trends for the captive and merchant global market for active pharmaceutical ingredients and intermediates.

A Shifting Landscape for the Global API Market

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

The PharmTech/PharmSource annual outsourcing survey results suggest that CDMOs may be getting complacent.

Stability Reigns in Contract Services

Increased pharmaceutical trade creates new challenges for regulatory oversight.

Evaluating China's Supply Chain

Claudia Roth, President of Vetter Development Service USA, discusses trends in single-use technology for clinical manufacturing.

Q&A with Claudia Roth, President, Vetter Development Service, USA

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Understanding the supply-chain challenge and coupling high-efficiency chromatographic techniques with information-rich detectors are leading to improvements in the management of extractables and leachables in parenteral drugs.

Experts from Novo Nordisk, Baxter Discuss Technological Advances in Addressing the Challenge of Extractables and Leachables

Contract service providers expand capabilities in API and finished product manufacturing to meet demand for high-potency drugs.

Gauging Investment in High-Potency Manufacturing

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

The industry may not be ready for India and China as regulatory issues emerge.

What Happened to Outsourcing in Asia?

The US and EU move forward with measures to fortify the pharmaceutical supply chain.